The pharmacokinetics of gefitinib in a Chinese Cancer population group: a virtual clinical trials population study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2021.05.008
Abstract: Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China and are expected to increase over the… read more here.
Keywords: pharmacokinetics gefitinib; cancer population; chinese cancer; cancer ... See more keywords